BiotechTube
Mobius Scientific

Mobius Scientific

San Diego, United States· Est.
mobius-scientific.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Mobius Scientific is a private, preclinical-stage biotech company founded in 2015, targeting the large unmet need in retinal diseases like age-related macular degeneration. The company is developing a proprietary platform for targeted biologics delivery to treat the root cause of vision loss. Its strategy involves leveraging groundbreaking technology to create a new treatment paradigm for the retina and potentially other tissues. As a pre-revenue entity, its success hinges on advancing its platform through clinical validation and securing strategic partnerships or funding.

OphthalmologyRetinal Diseases

Technology Platform

Proprietary platform for targeted biologics delivery to the retina, aiming to treat the root cause of disease with precision.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global AMD market is large and underserved, particularly for durable treatments that address disease root causes.
A successful targeted platform could enable superior therapeutics with best-in-class potential and expand into other retinal and non-retinal indications.

Risk Factors

High technical risk associated with novel drug delivery and targeting platforms; intense competition from large pharma and biotech in ophthalmology; dependency on raising sufficient capital to advance through costly clinical trials.

Competitive Landscape

Mobius operates in the highly competitive AMD space, competing against anti-VEGF giants (Regeneron, Roche) and newer therapies for geographic atrophy (Apellis, Iveric Bio/Astellas). It must differentiate through superior efficacy, durability, or mechanism by targeting disease biology more precisely.

More companies in United States →